Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q3 2023 · 10-Q
Revenue$10.14B$10.14B−2.6% vs Q3 2022 Net Income$1.44B$1.44B+0.1% vs Q3 2022 EPS Diluted$0.82$0.82+1.2% vs Q3 2022 Operating Income$1,647,000,000−6.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,317,000,000−43.1% Margins · derivedOperating margin16.2%−0.8 pt vs Q3 2022
Net margin14.2%+0.4 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 1, 2023 · 32 d after period end